Analysis of the sensitivity to endocrine therapy (SET) assay in the PALLAS adjuvant trial of palbociclib in HR+/HER2- breast cancer (ABCSG-42/AFT-05/BIG-14-13).
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Otto Metzger, Karla V. Ballman, Michael Gnant, Mark Watson, Eveline Chen, Kevin Tran, Patrick O'Brien, Dominik Hlauschek, Miguel Martin, Justin M Balko, Zbigniew Nowecki, Olwen Mary Hahn, Carsten Denkert, Christina Curtis, Yuan Liu, Amylou C. Dueck, Christian Fesl, Erica L. Mayer, Angela DeMichele, W. Fraser Fraser Symmans
Institutions: Alliance for Clinical Trials in Oncology, Dana-Farber Cancer Institute, Mayo Clinic, Medical University of Vienna, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center, Austrian Breast & Colorectal Cancer Study Group, GEICAM – Spanish Breast Cancer Group, Instituto de Investigación Sanitaria Gregorio Marañón, Vanderbilt University Medical Center, The Maria Sklodowska-Curie National Research Institute of Oncology, University of Chicago, Philipps University of Marburg, Stanford University, Pfizer (United States), University of Pennsylvania
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W4399121879